BioCentury
ARTICLE | Clinical News

Tezampanel: Additional Phase II data

July 7, 2008 7:00 AM UTC

Additional data from a double-blind, placebo-controlled, U.S. Phase II trial (NGX424MIG2001) in 306 patients showed that tezampanel improved the secondary endpoints of sustained headache response, abs...